Centessa Pharmaceuticals PLC
CNTA
查看详细走势图
25.680USD
+0.420+1.66%
收盘 12/24, 16:00（美东）报价延迟15分钟
3.45B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.66%
5天
+3.34%
1月
-11.33%
6月
+91.21%
今年开始到现在
+53.31%
1年
+51.95%
查看详细走势图
TradingKey Centessa Pharmaceuticals PLC股票评分
单位: USD 更新时间: 2025-12-24操作建议
Centessa Pharmaceuticals PLC当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名42/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价37.08。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Centessa Pharmaceuticals PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
15
位分析师
买入
评级
37.077
目标均价
+25.68%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Centessa Pharmaceuticals PLC亮点
亮点风险
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Centessa Pharmaceuticals PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Centessa Pharmaceuticals PLC简介
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
公司代码CNTA
公司Centessa Pharmaceuticals PLC
CEOSaha (Saurabh)
网址https://www.centessa.com/
常见问题
Centessa Pharmaceuticals PLC(CNTA)的当前股价是多少？
Centessa Pharmaceuticals PLC(CNTA)的当前股价是 25.680。
Centessa Pharmaceuticals PLC的股票代码是什么？
Centessa Pharmaceuticals PLC的股票代码是CNTA。
Centessa Pharmaceuticals PLC股票的52周最高点是多少？
Centessa Pharmaceuticals PLC股票的52周最高点是30.580。
Centessa Pharmaceuticals PLC股票的52周最低点是多少？
Centessa Pharmaceuticals PLC股票的52周最低点是9.600。
Centessa Pharmaceuticals PLC的市值是多少？
Centessa Pharmaceuticals PLC的市值是3.45B。
Centessa Pharmaceuticals PLC的净利润是多少？
Centessa Pharmaceuticals PLC的净利润为-235.76M。
现在Centessa Pharmaceuticals PLC(CNTA)的股票是买入、持有还是卖出？
根据分析师评级，Centessa Pharmaceuticals PLC(CNTA)的总体评级为买入，目标价格为37.077。
Centessa Pharmaceuticals PLC(CNTA)股票的每股收益（EPS TTM）是多少
Centessa Pharmaceuticals PLC(CNTA)股票的每股收益（EPS TTM）是-1.897。
相关品种
